Mounjaro SPC: what the Summary of Product Characteristics actually tells you

Why the SPC matters to you as a patient, not just to prescribers

Most people never seek out a medicine's SPC. That changes when a question arises that the pharmacy leaflet doesn't quite answer, a concern about a specific interaction, a query about what exactly the licensed indication covers, or a desire to understand the clinical trial data behind the approval rather than a headline figure. The Mounjaro SmPC fills that gap. It is the document the MHRA reviewed before granting UK marketing authorisation, and it remains the live legal reference for how the medicine may be prescribed.

Reading it requires some navigation. The SPC is structured in numbered sections: section 4.1 states the therapeutic indications (the exact conditions for which the medicine is licensed), section 4.2 sets out the posology (dose and administration), section 4.3 lists the contraindications, section 4.4 carries the special warnings and precautions, section 4.8 details undesirable effects, and section 5.1 describes the pharmacodynamic properties, including the trial evidence. Knowing where each type of information sits saves a lot of scrolling. You can read the full document on the Electronic Medicines Compendium (eMC), where it is kept up to date following any regulatory variation.

The practical value of reading it yourself is context: you arrive at a consultation with a clearer sense of what the prescriber is weighing, and the conversation tends to go further as a result.

What the licensed indications and eligibility criteria look like on paper

Section 4.1 of the Mounjaro SPC states two licensed indications: weight management in adults with a body mass index of 30 kg/m² or above, or 27 kg/m² or above when at least one weight-related comorbidity is present, alongside a reduced-calorie diet and increased physical activity; and the treatment of type 2 diabetes mellitus in adults, as an adjunct to diet and exercise. The comorbidity list drawn on in clinical practice includes conditions such as high blood pressure, type 2 diabetes, dyslipidaemia and obstructive sleep apnoea, though the SPC itself describes the licensed population rather than prescribing a definitive checklist.

The posology in section 4.2 describes a starting dose of 2.5 mg once weekly, used for the first four weeks as a tolerability period. The document does not set a fixed titration timeline beyond that, dose increases are made at the prescriber's discretion, informed by response and tolerability, through the 5 mg strength, where many patients begin to see meaningful therapeutic effect, and continuing through 7.5 mg, 10 mg, 12.5 mg and 15 mg. The SPC is clear that 2.5 mg is not a maintenance dose: it exists to reduce early gastrointestinal side effects rather than to produce the weight loss seen at higher doses.

For a fuller overview of how tirzepatide works as a dual GIP and GLP-1 receptor agonist, the mechanism section of the SPC (5.1) goes into considerably more depth than any leaflet summary. The NICE appraisal of tirzepatide (TA1026, published in December 2024) draws directly on the SPC's efficacy data when setting its recommendation criteria.

Side effects, contraindications and the SPC's safety language

Section 4.8 of the Mounjaro SPC lists undesirable effects by system organ class and frequency. Gastrointestinal effects head the list: nausea, vomiting, diarrhoea, constipation, abdominal discomfort and reflux are all classified as very common or common. These effects are typically most noticeable after starting treatment or after a dose increase, and for most people they ease within the first week or two. Injection-site reactions, fatigue, dizziness and headache also appear in this section.

The contraindications in section 4.3 are tight: hypersensitivity to tirzepatide or any excipient. The special warnings section (4.4) carries the material the prescriber reads most carefully, including pancreatitis, which the MHRA highlighted in a Drug Safety Update in January 2026 as a known but infrequent risk requiring urgent attention if severe, persistent stomach pain develops, particularly pain that reaches the back. Gallbladder problems, dehydration from prolonged vomiting, and thyroid findings in animal studies also feature here. The SPC does not restrict tirzepatide use in pancreatitis history outright, but section 4.4 makes clear this is a clinical judgement requiring careful prescriber assessment.

Mounjaro carries a Black Triangle (▼) designation, meaning the MHRA has asked for additional post-market monitoring, the SPC reflects this. If you experience an unexpected side effect, you can report it through the MHRA Yellow Card scheme. One practical habit worth forming: check that the SPC version on the eMC matches the batch date on your pen's packaging, the document is updated whenever new safety data reaches the regulator, and the two should align.

The SPC versus the PIL: which document to reach for, and when

The SPC and the Patient Information Leaflet cover similar ground but serve different readers. The PIL, found in every Mounjaro box, is written in plain language for patients and summarises the key safety information, storage instructions and what to do if a dose is missed. The SPC, by contrast, is written for healthcare professionals: it uses clinical terminology, references pharmacokinetics, and cites trial results with statistical precision. Both documents are generated from the same submission file, but the SPC carries detail the PIL omits, specifically the full trial data and the mechanistic pharmacology.

If your question is practical (what to do with a pen left out of the fridge, or how to handle a missed injection) the PIL is the right starting point. If your question is about the clinical rationale for a prescribing decision, the licensed population, or a specific drug interaction, the SPC is the document that will actually answer it. Questions about your own dose, schedule or response belong with your prescriber: neither document should substitute for that conversation.

The tirzepatide SPC page on this site walks through the document in plain English for people who want context rather than the raw regulatory text. For a broader overview of Mounjaro as a treatment, the Mounjaro treatment information page covers the essentials. If you're thinking about starting treatment and want a prescriber to assess whether it's right for you, starting a free consultation is the next step, a GPhC-registered prescriber reads every submission the same day it arrives.